XML 13 R7.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Balances, at Beginning of period at Dec. 31, 2023 $ 253,895 $ 4 $ 559,176 $ 347 $ (305,632)
Balances, at Beginning of period (in shares) at Dec. 31, 2023   54,992,784      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense, including employee stock purchase plan expense 15,818   15,818    
Issuance of shares under at-the-market offering, net of issuance costs 22,787   22,787    
Issuance of shares under at-the-market offering   1,772,278      
Issuance of shares under employee stock purchase plan 650   650    
Issuance of shares under employee stock purchase plan (in shares)   70,701      
Employee stock purchase plan expense 441   441    
Exercise of stock options 1,110   1,110    
Exercise of stock options (in shares)   359,897      
Vesting of restricted stock awards (in shares)   92,659      
Net unrealized (loss) gain on marketable securities 117     117  
Net loss (95,907)       (95,907)
Balances, at End of period at Sep. 30, 2024 198,911 $ 4 599,982 464 (401,539)
Balances, at End of period (in shares) at Sep. 30, 2024   57,288,319      
Balances, at Beginning of period at Dec. 31, 2023 253,895 $ 4 559,176 347 (305,632)
Balances, at Beginning of period (in shares) at Dec. 31, 2023   54,992,784      
Balances, at End of period at Dec. 31, 2024 408,964 $ 7 843,920 143 (435,106)
Balances, at End of period (in shares) at Dec. 31, 2024   74,312,608      
Balances, at Beginning of period at Jun. 30, 2024 227,163 $ 4 594,261 (118) (366,984)
Balances, at Beginning of period (in shares) at Jun. 30, 2024   57,246,411      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense, including employee stock purchase plan expense 5,572   5,572    
Employee stock purchase plan expense 54   54    
Exercise of stock options 95   95    
Exercise of stock options (in shares)   41,908      
Net unrealized (loss) gain on marketable securities 582     582  
Net loss (34,555)       (34,555)
Balances, at End of period at Sep. 30, 2024 198,911 $ 4 599,982 464 (401,539)
Balances, at End of period (in shares) at Sep. 30, 2024   57,288,319      
Balances, at Beginning of period at Dec. 31, 2024 408,964 $ 7 843,920 143 (435,106)
Balances, at Beginning of period (in shares) at Dec. 31, 2024   74,312,608      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense, including employee stock purchase plan expense 13,320   13,320    
Issuance of shares under employee stock purchase plan 748   748    
Issuance of shares under employee stock purchase plan (in shares)   206,609      
Exercise of stock options $ 477   477    
Exercise of stock options (in shares) 234,094 203,513      
Issuance cost associated with private equity placement $ (14)   (14)    
Exchange of common stock shares for pre-funded warrants (in shares)   (6,070,000)      
Net unrealized (loss) gain on marketable securities 383     383  
Net loss (116,390)       (116,390)
Balances, at End of period at Sep. 30, 2025 307,488 $ 7 858,451 526 (551,496)
Balances, at End of period (in shares) at Sep. 30, 2025   68,652,730      
Balances, at Beginning of period at Jun. 30, 2025 345,236 $ 7 854,194 314 (509,279)
Balances, at Beginning of period (in shares) at Jun. 30, 2025   68,627,886      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense, including employee stock purchase plan expense 4,250   4,250    
Exercise of stock options 7   7    
Exercise of stock options (in shares)   24,844      
Net unrealized (loss) gain on marketable securities 212     212  
Net loss (42,217)       (42,217)
Balances, at End of period at Sep. 30, 2025 $ 307,488 $ 7 $ 858,451 $ 526 $ (551,496)
Balances, at End of period (in shares) at Sep. 30, 2025   68,652,730